183 related articles for article (PubMed ID: 19624539)
21. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Barosi G; Gattoni E; Guglielmelli P; Campanelli R; Facchetti F; Fisogni S; Goldberg J; Marchioli R; Hoffman R; Vannucchi AM;
Am J Hematol; 2010 Aug; 85(8):616-9. PubMed ID: 20540156
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitors in mantle cell lymphoma.
Holkova B; Grant S
Best Pract Res Clin Haematol; 2012 Jun; 25(2):133-41. PubMed ID: 22687449
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
25. Images in clinical Medicine. Bortezomib-induced skin lesions.
Agterof MJ; Biesma DH
N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
[No Abstract] [Full Text] [Related]
26. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
27. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
29. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
30. Missing the target: ubiquitin ligase drugs stall.
Garber K
J Natl Cancer Inst; 2005 Feb; 97(3):166-7. PubMed ID: 15687356
[No Abstract] [Full Text] [Related]
31. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA
Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926
[TBL] [Abstract][Full Text] [Related]
32. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
33. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
35. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Davies FE; Wu P; Jenner M; Srikanth M; Saso R; Morgan GJ
Haematologica; 2007 Aug; 92(8):1149-50. PubMed ID: 17650451
[TBL] [Abstract][Full Text] [Related]
36. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Strauss SJ; Maharaj L; Hoare S; Johnson PW; Radford JA; Vinnecombe S; Millard L; Rohatiner A; Boral A; Trehu E; Schenkein D; Balkwill F; Joel SP; Lister TA
J Clin Oncol; 2006 May; 24(13):2105-12. PubMed ID: 16606971
[TBL] [Abstract][Full Text] [Related]
38. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
O'Connor OA; Portlock C; Moskowitz C; Hamlin P; Straus D; Gerecitano J; Gonen M; Dumitrescu O; Sarasohn D; Butos J; Neylon E; Mac-Gregor Cortelli B; Blumel S; Evens AM; Zelenetz AD; Wright J; Cooper B; Winter J; Vose J
Clin Cancer Res; 2010 Jan; 16(2):719-26. PubMed ID: 20068103
[TBL] [Abstract][Full Text] [Related]
39. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of bortezomib in patients with MALT lymphoma.
Troch M; Jonak C; Müllauer L; Püspök A; Formanek M; Hauff W; Zielinski CC; Chott A; Raderer M
Haematologica; 2009 May; 94(5):738-42. PubMed ID: 19336742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
